Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

This phase II trial tests the effect of tarlatamab in treating patients with small cell lung cancer (SCLC) that has spread from where it first started to other parts of the body (extensive-stage). SCLC is an aggressive cancer which has a low 5-year survival rate. Tarlatamab is a bispecific antibody that can bind to two different antigens at the same time. Tarlatamab binds to DLL3 which is a protein found on the surface of some types of tumor cells, including small-cell lung cancer, and to CD3 which is present on immune system T-cells (a type of white blood cell) and may interfere with the abil

Trial Details

NCT ID

NCT07423585

Phase

PHASE2

Sponsor

Asrar Alahmadi

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Biopsy Procedure
Biospecimen Collection
Computed Tomography
Echocardiography Test
Electronic Health Record Review
Magnetic Resonance Imaging

Locations (sample)

Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information
NOTE: HIPAA authorization may be included in the informed consent or obtained separately
Age ≥ 18 years at the time of consent
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →